Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ — On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the… Read More »Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor